View Older Stories
-
BioNTech authorizes $1 billion share repurchase program
-
BioNTech (BNTX) PT Lowered to $125 at BofA Securities
-
BioNTech SE (BNTX) Tops Q1 EPS by 20c, provides guidance
-
H.C. Wainwright Reiterates Buy Rating on BioNTech (BNTX)
-
BioNTech (BNTX) PT Raised to $130 at BofA Securities
-
BioNTech (BNTX) PT Lowered to $94 at Leerink Partners
-
BioNTech (BNTX) PT Lowered to $130 at H.C. Wainwright
-
US Judge blocks Trump Admin cuts to number of routinely recommended vaccines for children - Reuters
-
BioNTech (BNTX) PT Lowered to $128 at BMO Capital
-
Oppenheimer Reiterates Perform Rating on BioNTech (BNTX) following management changes
-
BioNTech (BNTX) PT Lowered to $167 at Clear Street: "absurd to be trading near cash"
-
BioNTech (BNTX) PT Lowered to $138 at Jefferies
-
BioNTech SE (BNTX) June 80 and September 55 puts active as share price down 17.7%
-
Truist Securities Reiterates Buy Rating on BioNTech (BNTX) following earnings, management changes
-
BioNTech (BNTX) PT Lowered to $128 at BofA Securities
-
Morgan Stanley Reiterates Overweight Rating on BioNTech (BNTX): "timing of announcement likely driving weakness in stock"
-
BioNTech co-founders to establish new mRNA company by 2026
-
BioNTech sues Moderna for U.S. patent infringement over covid vaccine MNEXspike - Court filing
-
Leerink Partners Downgrades BioNTech (BNTX) to Market Perform
-
Goldman Sachs Upgrades BioNTech (BNTX) to Buy, 'at the nexus of these significant developments occurring in the oncology field'
-
BMO Capital on BioNTech (BNTX): 'Catalyst-Rich 2026 to Spotlight Differentiation of Onc Assets'
-
BioNTech plans six new phase 3 oncology trials in 2026
-
FDA may add black box warning to Covid-19 vaccines, CNN says
-
H.C. Wainwright Reiterates Buy Rating on BioNTech (BNTX)
-
FDA probe of alleged deaths tied to Covid shots includes adults
-
FDA Probe Of Alleged Deaths Tied To Covid Shots Includes Adults
-
Clear Street Reiterates Buy Rating on BioNTech (BNTX)
-
Shares of vaccine makers drop after FDA memo flags reports of child deaths
-
BioNTech exchange offer for CureVac expires December 3
-
BioNTech (BNTX) PT Raised to $140 at H.C. Wainwright
-
BioNTech (BNTX) PT Lowered to $116 at TD Cowen
-
BioNTech (BNTX) PT Lowered to $181 at Clear Street
-
BioNTech (BNTX) PT Raised to $145 at Citi
-
BioNTech SE (BNTX) Misses Q3 EPS by 22c; lifts guidance
-
BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.
-
TD Cowen Reiterates Hold Rating on BioNTech (BNTX)
-
Trump on deal with Pfizer: we're going to be paying the lowest price, other drugmakers will commit in coming weeks
-
Trump says we’ll be reducing prices (of drugs) by a 100% and in some cases more
-
EU will still have 15% pharma tariff, not 100% - Bloomberg
-
Rfk Jr. Weighs Expansion Of Vaccine Injury Program: Adviser - Bloomberg
-
CDC Panel Votes Against Requiring Prescriptions For Covid Shots - Bloomberg
-
CDC Panel Votes To End Universal Recommendation For Covid Shots - Bloomberg
-
Kennedy To Change Childhood Vaccine Schedule In Sept: Monarez - Bloomberg
-
BioNTech SE (BNTX) call put ratio 1 call to 2.1 puts with a focus on September puts as share price down 8.1%
-
Pfizer, Moderna, BioNTech trade lower amid report of vaccine link to child deaths
-
H.C. Wainwright Reiterates Buy Rating on BioNTech (BNTX)
-
Pfizer and BioNTech report positive data for LP.8.1 COVID vaccine
-
BMO Capital Reiterates Outperform Rating on BioNTech (BNTX)
-
Clear Street on BioNTech (BNTX): 'BNT323 Clears Low Bar in Breast Cancer, But Incremental Validation Welcome'
-
BioNTech and DualityBio drug meets primary endpoint in phase 3 trial

